Ascendis Pharma Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
November 15, 2024 7:10 AM ESTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 3Q24 financial results, missing Street estimates on topline revenue and GAAP EPS, as the Skytrofa challenges that emerged... More
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
November 15, 2024 6:21 AM ESTOppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $190.00) while maintaining a Outperform rating.
The analyst comments "ASND reported 3Q net loss of 99.2M vs. our expected 110.2M as management continues to effectively manage expenses. Skytrofa revenue of... More
